Cellworks and CancerPOP Announce Data on Acute Lymphoblastic Leukemia from Tata Precision Oncology Program
Innovative Use of Computational Biology Modeling for Patients with Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Sets the Stage for Upcoming Clinical Trials
(Atlanta, GA) December 13, 2017 -- Cellworks Group, Inc. and CancerPOP, LLC, announced data from multiple studies using computational biology modeling to study acute lymphoblastic leukemia (ALL) during the American Society of Hematology 2017 Annual Meeting, as part of the Tata Precision Oncology Program supported by Tata Trusts. Tata Memorial Hospital, Mumbai (TMH) and Tata Medical Centre, Kolkata (TMC) are clinical partners of this program. The computer model predictions will be validated in retrospective and prospective clinical trials and in the lab by CancerPOP based in Gainesville, Florida along with TMH and TMC.
Abstracts from three studies demonstrate the use of computers to better understand ETP-ALL and screen for new drug regimens. The computer was taught to recognize ETP-ALL from all other forms of acute lymphoblastic leukemia, and identified certain genomic abnormalities distinguishing the two. The team then used the computer model of ETP-ALL to digitally screen for highly effective drug combinations. These new drug combinations were then validated in the laboratory. Results from these three studies will be used to design an upcoming clinical trial of patients with ETP-ALL.
Once the computer model is validated, this prediction technology will help doctors and patients both choose drugs with greatest likelihood of shrinking the cancer and avoid harmful drugs with low chance of success. For patients who aren’t responding to standard chemotherapy, and for patients whose cancer has relapsed, each patient’s computer model could be used to search for other FDA-approved drugs that may be effective.
Yatin Mundkur, CEO of Cellworks Group, said, “We would like to thank Tata Trusts and Tata Memorial Center for supporting this initiative. The Tata name has been associated with cancer care across India for several decades. Tata is well known for its business acumen and is associated with healthcare effectiveness. This project will build a precision medicine reference workflow which is starting to be deployed globally,” he added.
“Certain kinds of acute lymphoblastic leukemia, such as the early T-cell precursor subtype (also known as ETP-ALL), are very challenging to treat because its lack of initial response to standard chemotherapy, early relapse and poor patient survival outcomes,” said Christopher R. Cogle, M.D., professor at the University of Florida and Chief Executive Officer of CancerPOP. “These patients need more than standard chemotherapy, which prompted us to use a computational biology method to search for mechanisms of leukemia resistance and new treatment regimens.”
Presented abstracts included:
Abstract #1448; Poster; Saturday, December 9, 5:30 PM, Building A, Level 1, Hall A2. Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation (Turcotte, et al)
Abstract #1449; Poster; Saturday, December 9, 5:30 PM, Building A, Level 1, Hall A2. Computational Biology Model of ETP-ALL Used to Accurately Classify ETP-ALL Vs Non ETP-ALL Patients with Genomic Input (Drusbosky, et al)
Abstract #2708; Poster; Sunday, December 10; 6:00 PM, Building A, Level 1, Hall A2. Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options (Drusbosky, et al)
About Tata Trusts:
Celebrating its 125th anniversary this year, Tata Trusts is amongst India’s oldest, non-sectarian philanthropic organizations that work in several areas of community development. Since its inception, Tata Trusts has played a pioneering role in transforming traditional ideas of philanthropy to make impactful sustainable change in the lives of the communities served. Through direct implementation, co-partnership strategies and grant making, the Tata Trusts support and drive innovation in the areas of education; healthcare and nutrition; rural livelihoods; natural resources management; enhancing civil society and governance and media, arts, crafts and culture. Tata Trusts continue to be guided by the principles of its Founder, Jamsetji Tata and through his vision of proactive philanthropy; the Tata Trusts catalyse societal development while ensuring that initiatives and interventions have a contemporary relevance to the nation. For more information, please visit http://tatatrusts.org/
About Cellworks Group
Cellworks is a leader in Precision Medicine and the global pioneer of Therapeutic Responder Identification (TRI) technology. Using breakthrough modeling, simulation and AI techniques, TRI is advancing the application of Precision Medicine by providing clinicians with insight into which therapy will prove effective for a specific patient, and providing biopharma companies with tools to select clinical trial cohorts. TRI has the potential to transform lives by early adoption of successful therapies and accelerated availability of new drugs, while at the same time saving time and cost across the healthcare ecosystem. For more information, visit http://www.cellworks.life.
CancerPOP is a global personalized medicine company that performs genetic testing and precision oncology consulting for cancer patients and their doctors. For more information, please visit http://www.cancerpop.com. Follow CancerPOP on Social Media: @PrecisionOncologyProgram, @OncologyProgram, and LinkedIn.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
Hyperlinks are provided as a convenience and for informational purposes only. Cellworks and CancerPOP bear no responsibility for the security or content of external websites.
Source: Cellworks Group, Inc. and CancerPOP, LLC